Evogene reports Q3 EPS ($1.31) vs. (81c) last year

Reports Q3 revenue $1.8M vs. $3.8M last year. Revenues in Q3 2024 are mainly based on Casterra’s seed sales, while e revenues in Q3 2023 included a license fee payment of $2.5M received by Lavie Bio. CEO Ofer Haviv stated: “Our vision is to position Evogene (EVGN) as a pioneering company in the development of groundbreaking life-science products, rooted in microbes, small molecules, and genomics. This led to the development of our three proprietary AI tech-engines: MicroBoost AI, ChemPass AI and GeneRator AI…The significant expansion of the model training set is expected to lead to the following key benefits: Innovative molecules, more accurately addressing the specific product requirements; shortening development timelines; enhanced cost efficiency. I want to emphasize that the foundation model, which will be integrated into ChemPass AI, will remain the exclusive property of Evogene….In the passing quarter all our subsidiaries continued progressing in accordance with their work-plans, and we’re very proud of their achievements. With respect to activities in market segments not covered by our subsidiaries, I would like to share that, starting this past quarter, we have increased our efforts to establish partnerships with companies specializing in small-molecule drug development, leveraging the unique capabilities of ChemPass AI…”